CY1109333T1 - 3-[4- ετεροκυκλυλ-1,2,3-τριαζολ-1-υλ]-ν-αρυλο-βενζαμιδια ως αναστολεις της παραγωγης κυτοκινων για τη θεραπευτικη αγωγη χρονιων φλεγμονωδων νοσων - Google Patents

3-[4- ετεροκυκλυλ-1,2,3-τριαζολ-1-υλ]-ν-αρυλο-βενζαμιδια ως αναστολεις της παραγωγης κυτοκινων για τη θεραπευτικη αγωγη χρονιων φλεγμονωδων νοσων

Info

Publication number
CY1109333T1
CY1109333T1 CY20091100893T CY091100893T CY1109333T1 CY 1109333 T1 CY1109333 T1 CY 1109333T1 CY 20091100893 T CY20091100893 T CY 20091100893T CY 091100893 T CY091100893 T CY 091100893T CY 1109333 T1 CY1109333 T1 CY 1109333T1
Authority
CY
Cyprus
Prior art keywords
triazol
benzamide
heterocyclyl
inhibitors
aryl
Prior art date
Application number
CY20091100893T
Other languages
English (en)
Inventor
Derek Cogan
Ming-Hong Hao
Victor Marc Kamhi
Craig A Miller
M R Netherton
Alan D Swinamer
Original Assignee
Boehringer Ingelheim Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharmaceuticals, Inc. filed Critical Boehringer Ingelheim Pharmaceuticals, Inc.
Publication of CY1109333T1 publication Critical patent/CY1109333T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

Εδώ περιγράφονται ενώσεις του τύπου (I), οι οποίες αναστέλλουν την παραγωγή κυτοκινών που εμπλέκονται σε φλεγμονώδεις διεργασίες και συνεπώς είναι χρήσιμες για τη θεραπεία νόσων και παθολογικών καταστάσεων που εμπεριέχουν φλεγμονή όπως χρόνια φλεγμονώδης νόσος. Επίσης περιγράφονται διεργασίες για την παρασκευή αυτών των ενώσεων και φαρμακευτικών συνθέσεων που περιέχουν αυτές τις ενώσεις.
CY20091100893T 2004-03-09 2009-08-24 3-[4- ετεροκυκλυλ-1,2,3-τριαζολ-1-υλ]-ν-αρυλο-βενζαμιδια ως αναστολεις της παραγωγης κυτοκινων για τη θεραπευτικη αγωγη χρονιων φλεγμονωδων νοσων CY1109333T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55144504P 2004-03-09 2004-03-09
EP05724523A EP1725544B1 (en) 2004-03-09 2005-03-04 3-[4-heterocyclyl-1,2,3-triazol-1-yl]-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases

Publications (1)

Publication Number Publication Date
CY1109333T1 true CY1109333T1 (el) 2014-07-02

Family

ID=34962594

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100893T CY1109333T1 (el) 2004-03-09 2009-08-24 3-[4- ετεροκυκλυλ-1,2,3-τριαζολ-1-υλ]-ν-αρυλο-βενζαμιδια ως αναστολεις της παραγωγης κυτοκινων για τη θεραπευτικη αγωγη χρονιων φλεγμονωδων νοσων

Country Status (30)

Country Link
US (2) US7214802B2 (el)
EP (2) EP1887003A1 (el)
JP (1) JP4850824B2 (el)
KR (1) KR20060129077A (el)
CN (1) CN1930144A (el)
AR (1) AR048315A1 (el)
AT (1) ATE432273T1 (el)
AU (1) AU2005223738B2 (el)
BR (1) BRPI0508561A (el)
CA (1) CA2557856C (el)
CY (1) CY1109333T1 (el)
DE (1) DE602005014621D1 (el)
DK (1) DK1725544T3 (el)
EA (1) EA011634B1 (el)
EC (1) ECSP066833A (el)
ES (1) ES2327940T3 (el)
HR (1) HRP20090334T1 (el)
IL (1) IL177937A0 (el)
MY (1) MY143000A (el)
NO (1) NO20064120L (el)
NZ (1) NZ550148A (el)
PE (1) PE20051146A1 (el)
PL (1) PL1725544T3 (el)
PT (1) PT1725544E (el)
RS (1) RS50796B (el)
SI (1) SI1725544T1 (el)
TW (1) TW200602313A (el)
UA (1) UA85702C2 (el)
WO (1) WO2005090333A1 (el)
ZA (1) ZA200606177B (el)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009536618A (ja) * 2006-04-18 2009-10-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４−及び５−イミダゾリル環を含むサイトカイン阻害化合物の製造方法及びその中間体
US20080182837A1 (en) * 2006-07-07 2008-07-31 Steffen Steurer New chemical compounds
PL2090570T3 (pl) 2006-09-05 2012-03-30 Kyowa Hakko Kirin Co Ltd Pochodna imidazolu
WO2009003998A2 (en) * 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
CL2008001943A1 (es) * 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
US8278340B2 (en) 2007-11-27 2012-10-02 North Carolina State University Inhibition of biofilms in plants with imidazole derivatives
WO2009123753A1 (en) 2008-04-04 2009-10-08 North Carolina State University Inhibition of bacterial biofilms with imidazole-phenyl derivatives
WO2009131654A2 (en) * 2008-04-21 2009-10-29 North Carolina State University Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives
US20110212999A1 (en) * 2008-09-02 2011-09-01 Neurosearch A/S Triazole derivatives and their use as nicotinic acetylcholine receptor modulators
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
JP2012504137A (ja) 2008-09-29 2012-02-16 アボット・ラボラトリーズ インドール誘導体およびインドリン誘導体ならびにそれらの使用方法
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
KR20110063574A (ko) 2008-09-29 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 항증식성 화합물
WO2010077603A1 (en) * 2008-12-08 2010-07-08 North Carolina State University Inhibition and dispersion of biofilms in plants with imidazole-triazole derivatives
US8569316B2 (en) 2009-02-17 2013-10-29 Boehringer Ingelheim International Gmbh Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases
WO2010144686A1 (en) 2009-06-10 2010-12-16 North Carolina State University Inhibition and dispersion of bacterial biofilms with benzimidazole derivatives
WO2011008312A2 (en) 2009-07-14 2011-01-20 Abbott Laboratories Indole and indoline derivatives and methods of use thereof
US8778959B2 (en) 2009-12-17 2014-07-15 Abbvie Inc. AZA-bridged ring-fused indoles and indolines
WO2011084434A2 (en) 2009-12-17 2011-07-14 Abbott Laboratories Aza-ring fused indole and indoline derivatives
JP5734999B2 (ja) 2009-12-17 2015-06-17 アッヴィ・インコーポレイテッド 神経変性および神経精神医学的障害の治療に有用な架橋アミン環縮合インドールおよびインドリン
US9174949B2 (en) 2010-01-07 2015-11-03 Selexagen Therapeutics, Inc. Hedgehog inhibitors
WO2011085261A1 (en) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
EP2552905B1 (en) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH B-Raf kinase inhibitors
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
US8609669B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
US8466181B2 (en) * 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
MY162397A (en) * 2011-01-28 2017-06-15 4Sc Discovery Gmbh Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
CA2825779C (en) * 2011-01-28 2020-02-25 4Sc Discovery Gmbh Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
WO2012158399A1 (en) 2011-05-13 2012-11-22 Abbott Laboratories Condensed 2 - carbamoylpyridazinones as potassium channel modulators
JP6054869B2 (ja) 2011-07-29 2016-12-27 武田薬品工業株式会社 複素環化合物
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
BR112016010164A2 (pt) * 2013-11-05 2017-08-08 Bayer Cropscience Ag novos compostos para o combate aos ártropodes
WO2017108737A1 (en) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
WO2018102552A1 (en) 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
EP3759095A1 (en) 2018-03-01 2021-01-06 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
WO2020007729A1 (en) 2018-07-04 2020-01-09 Boehringer Ingelheim International Gmbh Triazole benzamide derivatives as gpr142 agonists
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
JP2023509260A (ja) 2019-08-14 2023-03-08 インサイト・コーポレイション Ｃｄｋ２阻害剤としてのイミダゾリルピリミジニルアミン化合物
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2022188792A1 (zh) * 2021-03-12 2022-09-15 四川科伦博泰生物医药股份有限公司 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2732967B1 (fr) 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
ES2239357T3 (es) * 1996-06-10 2005-09-16 MERCK & CO., INC. Imidazoles sustituidos que tienen actividad inhibidora de citoquinas.
JP4385414B2 (ja) * 1997-10-13 2009-12-16 アステラス製薬株式会社 アミド若しくはアミン誘導体
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
AU3387999A (en) * 1998-04-08 1999-10-25 Abbott Laboratories Pyrazole inhibitors of cytokine production
US6506747B1 (en) 1998-06-05 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
USRE45616E1 (en) 1998-10-13 2015-07-21 Covidien Lp Multi-channel non-invasive tissue oximeter
AU1130700A (en) 1998-10-23 2000-05-15 Dow Agrosciences Llc Insecticidal 1-(substituted pyridyl)-1,2,4-triazoles
US6451820B1 (en) 2000-03-23 2002-09-17 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenly)triazoles and their use as anti-inflammatory agents
US6498423B1 (en) 2001-06-27 2002-12-24 Welch Allyn, Inc. Lamp thermal control by directed air flow
US7297708B2 (en) 2001-09-06 2007-11-20 Bristol-Myers Squibb Company Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands
CA2458533C (en) 2001-10-09 2011-01-04 Tularik Inc. Imidazole derivates as anti-inflammatory agents
AU2003209388A1 (en) 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
DE602004029242D1 (en) 2003-05-01 2010-11-04 Bristol Myers Squibb Co Pyrazolamidverbindungen

Also Published As

Publication number Publication date
AU2005223738B2 (en) 2011-08-11
NO20064120L (no) 2006-09-26
BRPI0508561A (pt) 2007-08-14
PL1725544T3 (pl) 2009-10-30
US7214802B2 (en) 2007-05-08
JP4850824B2 (ja) 2012-01-11
EP1725544A1 (en) 2006-11-29
SI1725544T1 (sl) 2009-10-31
EP1887003A1 (en) 2008-02-13
IL177937A0 (en) 2006-12-31
RS50796B (sr) 2010-08-31
WO2005090333A1 (en) 2005-09-29
US20060079519A1 (en) 2006-04-13
NZ550148A (en) 2010-07-30
HRP20090334T1 (en) 2009-07-31
JP2007528395A (ja) 2007-10-11
ECSP066833A (es) 2006-11-24
EP1725544B1 (en) 2009-05-27
EA011634B1 (ru) 2009-04-28
UA85702C2 (ru) 2009-02-25
WO2005090333A8 (en) 2006-08-24
AR048315A1 (es) 2006-04-19
ZA200606177B (en) 2008-12-31
KR20060129077A (ko) 2006-12-14
CA2557856C (en) 2010-06-29
ATE432273T1 (de) 2009-06-15
TW200602313A (en) 2006-01-16
US7514458B2 (en) 2009-04-07
EA200601571A1 (ru) 2007-02-27
MY143000A (en) 2011-02-14
DE602005014621D1 (de) 2009-07-09
ES2327940T3 (es) 2009-11-05
CA2557856A1 (en) 2005-09-29
US20070142371A1 (en) 2007-06-21
CN1930144A (zh) 2007-03-14
DK1725544T3 (da) 2009-07-27
PE20051146A1 (es) 2006-02-02
PT1725544E (pt) 2009-07-02
AU2005223738A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
CY1109333T1 (el) 3-[4- ετεροκυκλυλ-1,2,3-τριαζολ-1-υλ]-ν-αρυλο-βενζαμιδια ως αναστολεις της παραγωγης κυτοκινων για τη θεραπευτικη αγωγη χρονιων φλεγμονωδων νοσων
NO2020031I1 (no) kobimetinib, inklusive farmasøytisk akseptable salter og solvater, særlig kobimetinib hemifumarat
EA200700902A1 (ru) 3-ариламинопиридиновые производные
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
MY138373A (en) Cytokine inhibitors
NO20062692L (no) Heterosykliske MEK inhibitorer og fremgangsmater for anvendelse derav
IS9037A (is) P38 kínasatálmar að stofni til úr 5 hluta heteróhring
DE602005002562D1 (de) Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
CY2013021I1 (el) Συνθεσεις για τη θεραπευτικη αγωγη γαστροεντερικων διαταραχων
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
ECSP034809A (es) Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc
ATE439837T1 (de) 5-gliedrige heterocyclische p-38 inhibitoren
EA200802050A1 (ru) Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
UA108222C2 (xx) СПОЛУКИ ЗАМІЩЕНОГО N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗОЛ$1,2-а]ПІРИДИН-3-КАРБОКСАМІДУ ЯК ІНГІБІТОРИ cFMS
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
EA200601884A1 (ru) Бета-карболины, применяемые для лечения воспалительных заболеваний
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
DE60332717D1 (de) Heterocyclische amid-derivate als cytokin-inhibitoren
AU2003294388A1 (en) 1, 2, 3- triazole amide derivatives as cytokine inhibitors
ATE463491T1 (de) Indolylmaleimid derivate
NO20054723L (no) Behandling av proliferative sykdommer med epofilonderivater og straling